Lab
Breast Cancer Gene Marker
search
Breast Cancer Gene Marker
, BRCA, Breast Cancer Gene Marker Testing Indications
See Also
BRCA1
BRCA2
Labs
Gene
Markers
Most common types (>20 mutations have been identified)
BRCA (
BRCA1
,
BRCA2
): 60% of
Breast Cancer
gene mutations
BRCA mutation
Prevalence
: 1 in 400 overall (1 in 40 in Ashkenazi jewish heritage)
Autosomal Dominant
inheritance
AT (
Ataxia Telangiectasia
) on
Chromosome
11
Single mutant copy
Confers 5 fold risk of
Breast Cancer
PTEN gene (Cowden syndrome)
CDH1 gene (hereditary diffuse
Gastric Cancer
)
TP53 gene (Li-Fraumeni syndrome)
STK11 gene (
Peutz-Jeghers Syndrome
)
Indications
BRCA testing (>5 to 10% pretest probability)
Person with
Family History
of
Breast Cancer
or
Ovarian Cancer
and known BRCA mutation
Ashkenazi jewish women
1st degree relative with
Breast
or
Ovarian Cancer
or
Two 2nd deg. relatives with
Breast
or
Ovarian Cancer
Non-Ashkenazi women
First degree relatives
Two with
Breast Cancer
(at least 1 under age 50)
One with bilateral
Breast Cancer
First or second degree relatives
Three with
Breast Cancer
Comorbid
Breast
and
Ovarian Cancer
at any age
Two or more with
Ovarian Cancer
Extended family
Breast Cancer
in any male relative (third degree or closer)
Personal history of
Breast Cancer
Breast Cancer
diagnosed at age <45 years
Breast Cancer
diagnosed at age <50 years AND at least one additional criteria
At least one blood relative (third degree or closer) with
Breast
or
Ovarian Cancer
(or variants)
Two primary
Breast Cancer
s
Limited
Family History
Breast Cancer
diagnosed at age <60 years AND at least one additional criteria
Triple negative
Breast Cancer
Breast Cancer
diagnosed at any age AND at least one additional criteria
Ethnicity with high mutation frequency (e.g. Ashkenazi Jewish)
Personal history or
Family History
(third degree or closer) of male
Breast Cancer
At least two blood relatives (third degree or closer) on same side of family AND one of the following
Breast
or
Ovarian Cancer
(or one at age <50 years)
Pancreatic Cancer
or aggressive
Prostate Cancer
(Gleason>=7)
Personal history of other cancers
Personal history of epithelial ovarian, fallopian or primary peritoneal cancer
Pancreatic Cancer
or aggressive
Prostate Cancer
(Gleason>=7)
Management
Known
BRCA1
or
BRCA2
carrier
BRCA1
Lifetime Risks
See
BRCA1
Breast Cancer
in Women: 50-80%
Second primary
Breast Cancer
27% within 5 years
Breast Cancer in Men
: 1 to 2%
Ovarian Cancer
risk: 18 to 40% (up to 54% in some studies)
Prostate Cancer
: <30%
Pancreatic Cancer
: 1 to 3%
BRCA2
Lifetime Risks
See
BRCA2
Breast Cancer
in Women: 40 to 70% (up to 90% in some studies)
Second primary
Breast Cancer
12% within 5 years (40 to 50% at 20 years)
Breast Cancer in Men
: 5 to 10%
Ovarian Cancer
risk: 11-20%
Prostate Cancer
: <40%
Pancreatic Cancer
: 2 to 7%
Melanoma
Breast
Cancer
Risk Management
in Women
Surveillance starting at age 25 years
Self Breast Exam
Monthly (start at age 18 years)
Clinical Breast Exam
every 6 months
Breast MRI
with contrast yearly (start at age 25 years)
May perform
Mammogram
as an alternative to MRI for age 25 to 30 years
As of age 30 years, perform MRI and
Mammogram
Mammogram
yearly (start at age 30 years)
Perform BOTH MRI and
Mammogram
as of age 30 years
Prophylactic
Mastectomy
Breast Cancer
can still occur
References
Garber in Harris (1996) Diseases
Breast
p. 335-41
Ovarian Cancer
Risk Management
No clear evidence-based guidelines
Screening typically identifies
Ovarian Cancer
in late stages (stage 3 and 4)
Prophylactic Oophorectomy
is the most effective strategy
NCCN guidelines (esp.
BRCA1
) for intact ovaries
Test every 6 months from age 35
Tests
Transvaginal Ultrasound
CA-125
Men with BRCA positive status
Self Breast Exam
monthly starting at age 35 years
Mammogram
(if enough
Breast
tissue or
Gynecomastia
to allow for
Mammogram
)
Start yearly at age 50 years (or 10 years before youngest relative with
Breast Cancer
)
Prostate Cancer Screening
starting at age 40 years (
BRCA2
)
Melanoma
Skin Cancer
screening
Annual full body skin exam
Skin
Cancer Prevention
(
Sunscreen
and other measures to reduce UV exposure)
References
Lypas (2018) Forum of Clinical Oncology 7(2): 16-24
Casaubon (2022) BRCA 1 and 2, StatPearls, Treasure Island +PMID: 29262038 [PubMed]
Daly (2021) J Natl Compr Canc Netw 19(1): 77-102 [PubMed]
Type your search phrase here